Skip to main content
Erschienen in: Wiener klinische Wochenschrift 5-6/2016

01.03.2016 | short report

All-comer treatment with bioresorbable vascular scaffold

verfasst von: Matjaž Bunc, Miha Mrak, Prof. Dr. Peter Rakovec

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 5-6/2016

Einloggen, um Zugang zu erhalten

Summary

Background

Bioresorbable vascular scaffolds (BVS) could overcome drug-eluting stents (DES) drawbacks connected with their permanent presence in the vessel wall. Studies exploring the clinical use of BVS are limited to the patients presenting with noncomplex, short and stable lesions. There are no prospective and randomized studies available in all-comer patients.

Methods and results

We analyzed 31 patients, who received at least one BVS (Absorb) between September 1, 2012 and November 1, 2014. Median follow-up period was 424 days. In one (3.2 %) patient, we performed a target vessel revascularization (TVR). The death rate was 6.5 %. One (3.2 %) patient, who received both BVS and a bare metal stent (BMS), died of an acute stent thrombosis 8 days after the initial procedure. One (3.2 %) patient died of a non-cardiac death. We did not encounter any target lesion revascularization (TLR) or myocardial infarction (MI). The major adverse cardiac events (MACE) rate was 3.2 %.

Conclusions

Implantation of BVS is a safe treatment option. Lesions should be carefully selected and prepared before BVS implantation. We need more data about the safety of BVS and BMS overlapping.
Literatur
1.
Zurück zum Zitat Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014;64:2541–51.CrossRefPubMed Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014;64:2541–51.CrossRefPubMed
2.
Zurück zum Zitat Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897–910.CrossRefPubMed Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897–910.CrossRefPubMed
3.
Zurück zum Zitat Latib A, Costopoulos C, Naganuma T, et al. Which patients could benefit the most from bioresorbable vascular scaffold implant: from clinical trials to clinical practice. Minerva Cardioangiol. 2013;61:255–62.PubMed Latib A, Costopoulos C, Naganuma T, et al. Which patients could benefit the most from bioresorbable vascular scaffold implant: from clinical trials to clinical practice. Minerva Cardioangiol. 2013;61:255–62.PubMed
4.
Zurück zum Zitat Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16–25.CrossRefPubMed Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16–25.CrossRefPubMed
5.
Zurück zum Zitat Windecker S, Kolh P, Alfonso F, et al. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2014;35:2541–619.CrossRefPubMed Windecker S, Kolh P, Alfonso F, et al. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2014;35:2541–619.CrossRefPubMed
6.
Zurück zum Zitat Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6:999–1009.CrossRefPubMed Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6:999–1009.CrossRefPubMed
7.
Zurück zum Zitat Džavík V, Colombo A. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing. JACC Cardiovasc Interv. 2014;7:81–8.CrossRefPubMed Džavík V, Colombo A. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing. JACC Cardiovasc Interv. 2014;7:81–8.CrossRefPubMed
8.
Zurück zum Zitat Wiebe J, Liebetrau C, Dörr O, et al. Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. Int J Cardiol. 2015;179:90–4.CrossRefPubMed Wiebe J, Liebetrau C, Dörr O, et al. Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. Int J Cardiol. 2015;179:90–4.CrossRefPubMed
9.
Zurück zum Zitat Dudek D, Rzeszutko Ł, Zasada W, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn. 2014;124:669–77.PubMed Dudek D, Rzeszutko Ł, Zasada W, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn. 2014;124:669–77.PubMed
10.
Zurück zum Zitat Gori T, Schulz E, Hink U, et al. Early outcome after implantation of absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014;9:1036–41.CrossRefPubMed Gori T, Schulz E, Hink U, et al. Early outcome after implantation of absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014;9:1036–41.CrossRefPubMed
11.
Zurück zum Zitat Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43–54.CrossRefPubMed Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43–54.CrossRefPubMed
12.
Zurück zum Zitat Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144–53.CrossRefPubMed Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144–53.CrossRefPubMed
13.
Zurück zum Zitat Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015;8:189–97.CrossRefPubMed Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015;8:189–97.CrossRefPubMed
14.
Zurück zum Zitat Kranjec I, Dzananovic DZ. Acute ischemic events are frequent after primary coronary stenting. J Cardiovasc Med. 2015;16:178–88.CrossRef Kranjec I, Dzananovic DZ. Acute ischemic events are frequent after primary coronary stenting. J Cardiovasc Med. 2015;16:178–88.CrossRef
15.
Zurück zum Zitat Rivero F, Bastante T, Cuesta J, et al. Treatment of in-stent restenosis with bioresorbable vascular scaffolds: optical coherence tomography insights. Can J Cardiol. 2015;31:255–9.CrossRefPubMed Rivero F, Bastante T, Cuesta J, et al. Treatment of in-stent restenosis with bioresorbable vascular scaffolds: optical coherence tomography insights. Can J Cardiol. 2015;31:255–9.CrossRefPubMed
16.
Zurück zum Zitat Naganuma T, Latib A, Panoulas VF, et al. Why do we need post-dilation after implantation of a bioresorbable vascular scaffold even for a soft lesion? JACC Cardiovasc Interv. 2014;7:1070–2.CrossRefPubMed Naganuma T, Latib A, Panoulas VF, et al. Why do we need post-dilation after implantation of a bioresorbable vascular scaffold even for a soft lesion? JACC Cardiovasc Interv. 2014;7:1070–2.CrossRefPubMed
Metadaten
Titel
All-comer treatment with bioresorbable vascular scaffold
verfasst von
Matjaž Bunc
Miha Mrak
Prof. Dr. Peter Rakovec
Publikationsdatum
01.03.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 5-6/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0914-4

Weitere Artikel der Ausgabe 5-6/2016

Wiener klinische Wochenschrift 5-6/2016 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungen